Brief: Sanofi: Venglustat Earns Breakthrough Therapy Designation In U.S.
18/03/2026 06:05
March 18 (Reuters) - Sanofi SA SASY.PA: SANOFI’S VENGLUSTAT EARNS BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR TYPE 3 GAUCHER DISEASE Source text: ID:nGNXc92NGS Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes